spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  VIMOVO 

 HSMN NewsFeed - 29 Nov 2018
Nuvo Pharmaceuticals(TM) Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 14 Nov 2018
Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Aug 2018
Nuvo Pharmaceuticals(TM) Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 4 Jan 2018
OrphoMed Appoints Gastroenterology Expert and Industry Veteran Mark Sostek, M.D. as Chief Medical Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 19 Dec 2016
Aralez Announces Commercial Launch Of BLEXTEN(TM) In Canada
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Apr 2016
Aralez Receives Health Canada Approval For BLEXTEN(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Mar 2016
Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA(TM)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 14 Sep 2015
POZEN Appoints James P. Tursi, M.D. Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jul 2015
POZEN Appoints Scott Charles Senior Vice President of Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2015
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Apr 2015
Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Mar 2015
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Feb 2015
Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 May 2014
POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Mar 2014
Horizon Pharma to Acquire Vidara Therapeutics International Ltd. and Become Horizon Pharma plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Mar 2014
Horizon Pharma Names Robert F. Carey Executive Vice President and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Nov 2013
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 22 Mar 2012
POZEN Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of PA32540
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 12 Jul 2011
POZEN Announces Tomas S. Bocanegra, M.D. as Head of Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2011
Preliminary Injunction Ordered in POZEN Treximet Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 22 Feb 2011
POZEN Announces Addition to Commercial Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2010
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 14 Sep 2009
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.